Gilead announces phase I/II data insufficient for marketing clearance of FORVADE topical gel to treat refractory herpes in patients with AIDS.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000287:Administration, Topical; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000627:therapeutic use; D000077404:Cidofovir; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D003596:Cytosine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006561:Herpes Simplex / Q000188:drug therapy*; D006801:Humans; D017387:Investigational New Drug Application; D063065:Organophosphonates; D009943:Organophosphorus Compounds / Q000008:administration & dosage* / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000998:Antiviral Agents; D063065:Organophosphonates; D009943:Organophosphorus Compounds; D003596:Cytosine; D000077404:Cidofovir